Bryce Point Capital LLC Purchases New Holdings in Envista Holdings Co. (NYSE:NVST)

Bryce Point Capital LLC acquired a new position in shares of Envista Holdings Co. (NYSE:NVST) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 30,579 shares of the company’s stock, valued at approximately $590,000.

Several other hedge funds and other institutional investors also recently modified their holdings of NVST. Franklin Resources Inc. increased its holdings in Envista by 72.6% in the fourth quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after buying an additional 2,882,844 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Envista by 9.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,271,175 shares of the company’s stock worth $63,101,000 after purchasing an additional 283,415 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Envista by 2.5% in the third quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company’s stock worth $57,233,000 after purchasing an additional 71,435 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Envista by 8.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,317,631 shares of the company’s stock valued at $44,707,000 after purchasing an additional 179,600 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Envista during the fourth quarter worth $38,052,000.

Envista Stock Up 2.3 %

NVST opened at $17.49 on Thursday. The company has a market capitalization of $3.01 billion, a PE ratio of -2.69, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. Envista Holdings Co. has a fifty-two week low of $15.15 and a fifty-two week high of $23.00. The business has a 50-day moving average of $19.40 and a 200-day moving average of $19.57.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities research analysts forecast that Envista Holdings Co. will post 1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on NVST shares. Morgan Stanley reduced their price target on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a report on Thursday, March 6th. JPMorgan Chase & Co. dropped their price target on shares of Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Piper Sandler increased their price objective on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Mizuho assumed coverage on shares of Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective for the company. Finally, Jefferies Financial Group upped their target price on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $20.18.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.